Human Albumin Baxalta (Human Plasma Protein)

Human Albumin Baxalta is a sterile solution for injection that contains human plasma protein (human albumin) as the active ingredient. The product is supplied in an unspecified strength and is intended for intravenous administration. It is classified as a plasma volume expander and is available by prescription in the European Union. The formulation is derived from pooled human plasma and is used to support patients with low plasma protein levels.

Human Albumin Baxalta is indicated for clinical situations that require rapid restoration of intravascular volume or plasma protein concentration.

- Treatment of hypovolemia due to acute blood loss, surgery, or trauma. - Management of hypoalbuminemia associated with chronic liver disease, nephrotic syndrome, or malnutrition. - Supportive care for patients with extensive burns to maintain oncotic pressure. - Resuscitation in shock states where plasma expansion is needed. - Adjunct therapy during plasma exchange procedures. - Prevention of circulatory collapse in patients undergoing major abdominal or cardiac surgery.

Adverse reactions to Human Albumin Baxalta are generally related to the infusion process or to the protein source.

Common: - Mild fever or chills during or shortly after infusion. - Headache or dizziness. - Nausea, vomiting, or abdominal discomfort. - Transient hypertension or hypotension. - Localized erythema or swelling at the injection site. - Mild rash or pruritus at distant sites.

Serious: - Anaphylactic or severe allergic reactions, including urticaria and bronchospasm. - Acute hemolysis or renal impairment. - Volume overload leading to pulmonary edema. - Thromboembolic events such as deep vein thrombosis. - Transmission of infectious agents (theoretical risk despite screening). - Severe hypotension requiring vasopressor support. These events are typically identified during monitoring and may resolve with appropriate medical management.

When prescribing Human Albumin Baxalta, clinicians should evaluate patient history and monitor for conditions that could be aggravated by plasma volume expansion.

- Assess for fluid overload, congestive heart failure, or severe renal disease before administration. - Verify that the patient has no known hypersensitivity to albumin or any component of the solution. - Use caution in patients with active infection or sepsis, as volume expansion may affect hemodynamics. - Monitor vital signs and fluid balance during and after infusion, especially in critically ill individuals. - Adjust dose or infusion rate in patients with pulmonary hypertension or compromised cardiac function. - Consider the risk of electrolyte disturbances, particularly hypernatremia, when large volumes are infused.

Human Albumin Baxalta may interact with other intravenously administered agents, and certain combinations require avoidance or careful monitoring.

Avoid: - Concurrent use with other plasma expanders (e.g., hydroxyethyl starch) due to risk of volume overload. - Simultaneous infusion of high‑dose diuretics that may precipitate rapid intravascular volume shifts. - Administration with blood products containing incompatible antibodies.

Use with caution: - Co‑administration with vasopressors; monitor blood pressure closely. - Use alongside nephrotoxic drugs; assess renal function regularly. - Combination with anticoagulants; observe for bleeding tendencies. - Overlap with other colloid solutions; adjust total colloid load.